PureTech Health plc Share Price & Technical Analysis
PRTC · $17.25 (0.00%)
Healthcare / Biotechnology
$17.25
0.00%
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The com…
Price chart
Seasonality
May has 4 positive and 1 negative years (last 5 years shown)
-5% return in May, 10% avg return in past 3 year May month.
0% return in 2026, 0% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 13% | -10% | -13% | 16% | -5% | – | – | – | – | – | – | – | 0% |
| 25 | 0% | -5% | 8% | -10% | 4% | -7% | 9% | -7% | 16% | -6% | -7% | 1% | -3% |
| 24 | -7% | 1% | 10% | -7% | 18% | -18% | -4% | 4% | -5% | 3% | 6% | -15% | -15% |
| 23 | 0% | -6% | 8% | -10% | 7% | 8% | -4% | -18% | -4% | -16% | 11% | 42% | 18% |
| 22 | 0% | -23% | -15% | -18% | 7% | -3% | 17% | 25% | -7% | 5% | 25% | -6% | 8% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$419.29M
P/E ratio
—
52W high
$19.92
52W low
$14.50
Volume
6,761
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is PureTech Health plc share price today?
- PureTech Health plc (PRTC) last traded around $17.25 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PRTC have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PRTC. Download the app for real-time alerts.
- How can I analyze PureTech Health plc stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.